Overview

Oxaliplatin in Treating Patients With Metastatic Breast Cancer

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This phase 0/II trial studies the effect of carbon C 14 oxaliplatin in tumor tissue and blood and the side effects and how well oxaliplatin works in treating patients with metastatic breast cancer. DNA analysis of tumor tissue and blood samples from patients receiving carbon C 14 oxaliplatin may help doctors predict how well patients will respond to treatment with oxaliplatin. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of California, Davis
Collaborator:
National Cancer Institute (NCI)
Treatments:
Oxaliplatin